Regeneron Reports Third Quarter 2014 Financial and Operating Results
Regeneron Announces Upcoming 2014 Investor Conference Presentations
Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
We have an extensive pipeline of investigational product candidates that are progressing through all stages of human clinical trials. Our product candidates address many serious medical conditions including cancer, eye diseases, inflammatory diseases, pain, cardiovascular diseases, and allergic conditions.
We are committed to
to science, to our people, and
above all, to the patients
whom we serve.
Quality Compliance Specialist